Skip to content

Immunofusion: what changed

BE 0804.563.629NACE 72.109, Other research and development on natural sciencesOther company

Position among the sector peers

What moved between 2024 and 2025

Net result for the year
-€42,606
2024 · -€72,858+€30,252
Equity
-€126,049
2024 · -€83,443-€42,606
Cash
€22,275
2024 · €3,391+€18,884
Balance sheet total
€32,131
2024 · €4,761+€27,370

Largest movements

2024 to 2025
Assets
  • Cash +€18,884

    up €18,884 (+557%), from €3,391 to €22,275

    mainly Other debts (+€51,313) and Trade debts (+€14,963)

  • Receivables within one year +€8,486

    up €8,486 (+619%), from €1,370 to €9,856

    of which Other amounts receivable: +€7,123

Equity and liabilities
  • Other debts +€51,313

    up €51,313 (+58.7%), from €87,478 to €138,791

  • Profit (loss) carried forward -€42,606

    down €42,606 (-49.3%), from -€86,443 to -€129,049

  • Trade debts +€14,963

    up €14,963 (+2,061%), from €726 to €15,689

  • Accrued charges and deferred income +€3,700

    first reported in 2025, at €3,700

Income statement
  • Gross operating margin +€30,174

    up €30,174 (+41.5%), from -€72,670 to -€42,496

Change in the result, 2024 to 2025

effect on the result

For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.

Result 2024 -€72,858
Gross operating margin +€30,174
Other operating charges +€118
Financial charges -€40
Result 2025 -€42,606
raises the resultlowers the result

Derived cash bridge

cash 2024 to 2025

The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.

From operations +€18,884
Investment €0
Financing +€0
Cash 2024 €3,391
Net result for the year -€42,606
Receivables within one year -€8,486
Trade debts +€14,963
Other debts +€51,313
Accrued charges and deferred income +€3,700
Contributions, distributions and other +€0
Cash 2025 €22,275
brings cash intakes cash out
Every line side by side 24 lines
Line Code 2024 2025 Change %
Total assets 20/58 €4,761 €32,131 +€27,370 +575%
Current assets 29/58 €4,761 €32,131 +€27,370 +575%
Amounts receivable within one year 40/41 €1,370 €9,856 +€8,486 +619%
Trade receivables 40 - €1,363 +€1,363
Other amounts receivable 41 €1,370 €8,493 +€7,123 +520%
Cash at bank and in hand 54/58 €3,391 €22,275 +€18,884 +557%
Total equity and liabilities 10/49 €4,761 €32,131 +€27,370 +575%
Equity 10/15 -€83,443 -€126,049 -€42,606 -51.1%
Contributions 10/11 €3,000 €3,000 = 0.0%
Profit (loss) carried forward 14 -€86,443 -€129,049 -€42,606 -49.3%
Amounts payable 17/49 €88,204 €158,180 +€69,976 +79.3%
Amounts payable within one year 42/48 €88,204 €154,480 +€66,276 +75.1%
Trade debts 44 €726 €15,689 +€14,963 +2,061%
Suppliers 440/4 €726 €15,689 +€14,963 +2,061%
Other amounts payable 47/48 €87,478 €138,791 +€51,313 +58.7%
Accrued charges and deferred income 492/3 - €3,700 +€3,700
Other operating charges 640/8 €118 €0 -€118 -100%
Gross operating margin 9900 -€72,670 -€42,496 +€30,174 +41.5%
Operating profit (loss) 9901 -€72,788 -€42,496 +€30,292 +41.6%
Financial charges 65/66B €70 €110 +€40 +57.3%
Recurring financial charges 65 €70 €110 +€40 +57.3%
Profit (loss) for the period before taxes 9903 -€72,858 -€42,606 +€30,252 +41.5%
Profit (loss) for the period 9904 -€72,858 -€42,606 +€30,252 +41.5%
Profit (loss) for the period to be appropriated 9905 -€72,858 -€42,606 +€30,252 +41.5%

Value

latest balance sheet 31-12-2025 · indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice

Capitalisation rate 12% result over 3 years earnings weight 50%

Worked out with Checked's starting values, not your estimate and not market data. Change the assumptions: the value follows.

The filed figures and these assumptions give no positive value. The adjusted equity and the average result are both zero or negative.

Part of the calculation comes out below zero. A shareholding is never worth less than zero, so the floor is zero.

Adjusted equity -€126,049

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
-€126,049
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
-€126,049

Capitalised earnings

net result for the year (9904)
2025
-€42,606
2024
-€72,858
2023
-€13,585
Average result
-€43,016
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
not meaningful, as the average result is zero or negative

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The result is not corrected for the manager's pay. If the company pays less or more than a market salary, the capitalised earnings are too high or too low.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 17 November 2026 via checked.be.